ValoTx Secures Full EIC Transition Funding
with Support from Nordic Innovators
Our client Valo Therapeutics Oy (Valo Tx) from Helsinki, Finland, has been awarded EUR 2.23 million from the highly competitive EIC Transition programme. The grant will support the advancement of their innovative PeptiCHIP technology — an innovation that holds immense promise for the future of personalised immunotherapies.
ValoTx Is Developing a Novel, Adaptable Immunotherapies for Cancer and Infectious
PeptiCHIP rapidly identifies a tumor’s antigen presentation profile to drive development of novel personalised immunotherapies tailored to each patient, which can transform lives.
Identifying the right antigens remains one of the most significant challenges in cancer immunotherapy. PeptiCHIP directly addresses this by providing precise insights into tumour-specific antigens, supporting both ValoTx's own clinical development and strategic collaborations with other biotech innovators.
EIC Transition Makes a Difference to the Project
The project will be fully 100% funded by the European Innovation Council as a non-dilutive grant. In addition, Valo Tx will benefit from the EIC Business Acceleration Services, which provide access to expert coaching, mentoring, and networking opportunities.
EIC Transition supports innovation activities that go beyond the proof-of-principle stage, bridging the gap between lab-based research and real-world application. We are proud to have played a role in their grant-writing process helping ValoTx take this important step toward transforming immunotherapy.